Meyer Andrew Hollman, Chief Business Officer at Janux Therapeutics ($JANX), made eight open market sales of company shares over the past year, totaling nearly $944,000. His most recent sale occurred on January 2, 2026. These transactions rank him 5,067th among 11,678 individual insiders by sale value in our database, where the average is $8.6 million across about 6.4 trades per insider. Hollman recorded no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 2, 2026 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | S | Common Stock | 1879 | $13.73 | 83,095.0000 | 62,023,685 | 2.21% | 0.00% |
| Dec. 1, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | S | Common Stock | 633 | $33.52 | 84,974.0000 | 62,023,685 | 0.74% | 0.00% |
| Dec. 1, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | M | Common Stock | 3333 | $10.59 | 88,307.0000 | 62,023,685 | 3.92% | 0.01% |
| Dec. 1, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | M | Stock Option (right to buy) | 3333 | $0.00 | 114,768.0000 | 62,023,685 | 2.82% | 0.01% |
| Dec. 1, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | S | Common Stock | 2700 | $32.85 | 85,607.0000 | 62,023,685 | 3.06% | 0.00% |
| Nov. 14, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | M | Stock Option (right to buy) | 3333 | $0.00 | 118,101.0000 | 62,023,685 | 2.74% | 0.01% |
| Nov. 14, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | M | Common Stock | 3333 | $10.59 | 88,307.0000 | 62,023,685 | 3.92% | 0.01% |
| Nov. 14, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | S | Common Stock | 3333 | $30.00 | 84,974.0000 | 62,023,685 | 3.77% | 0.01% |
| Oct. 28, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | M | Stock Option (right to buy) | 9999 | $0.00 | 77,333.0000 | 62,023,685 | 11.45% | 0.02% |
| Oct. 28, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | M | Common Stock | 6666 | $10.59 | 98,804.0000 | 62,023,685 | 7.23% | 0.01% |
| Oct. 28, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | M | Common Stock | 9999 | $4.21 | 92,138.0000 | 62,023,685 | 12.17% | 0.02% |
| Oct. 28, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | M | Stock Option (right to buy) | 6666 | $0.00 | 121,434.0000 | 62,023,685 | 5.20% | 0.01% |
| Oct. 28, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | S | Common Stock | 16665 | $30.06 | 82,139.0000 | 62,023,685 | 16.87% | 0.03% |
| May 1, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | S | Common Stock | 2933 | $31.95 | 82,539.0000 | 53,751,480 | 3.43% | 0.01% |
| May 1, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | M | Stock Option (right to buy) | 3333 | $0.00 | 87,332.0000 | 53,751,480 | 3.68% | 0.01% |
| May 1, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | S | Common Stock | 400 | $32.60 | 82,139.0000 | 53,751,480 | 0.48% | 0.00% |
| May 1, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | M | Common Stock | 3333 | $4.21 | 85,472.0000 | 53,751,480 | 4.06% | 0.01% |
| April 21, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | S | Common Stock | 3334 | $30.00 | 82,139.0000 | 53,751,480 | 3.90% | 0.01% |
| April 21, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | M | Common Stock | 3334 | $4.21 | 85,473.0000 | 53,751,480 | 4.06% | 0.01% |
| April 21, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | M | Stock Option (right to buy) | 3334 | $0.00 | 90,665.0000 | 53,751,480 | 3.55% | 0.01% |
| March 3, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | M | Stock Option (right to buy) | 3334 | $0.00 | 93,999.0000 | 53,751,480 | 3.43% | 0.01% |
| March 3, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | M | Common Stock | 3334 | $4.21 | 85,473.0000 | 53,751,480 | 4.06% | 0.01% |
| March 3, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | S | Common Stock | 2433 | $31.88 | 83,040.0000 | 53,751,480 | 2.85% | 0.00% |
| March 3, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | S | Common Stock | 901 | $32.85 | 82,139.0000 | 53,751,480 | 1.09% | 0.00% |
| Feb. 3, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | S | Common Stock | 816 | $42.77 | 82,239.0000 | 53,751,480 | 0.98% | 0.00% |
| Feb. 3, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | S | Common Stock | 2418 | $42.08 | 83,055.0000 | 53,751,480 | 2.83% | 0.00% |
| Feb. 3, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | S | Common Stock | 100 | $43.60 | 82,139.0000 | 53,751,480 | 0.12% | 0.00% |
| Feb. 3, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | M | Stock Option (right to buy) | 3334 | $0.00 | 97,333.0000 | 53,751,480 | 3.31% | 0.01% |
| Feb. 3, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | M | Common Stock | 3334 | $4.21 | 85,473.0000 | 53,751,480 | 4.06% | 0.01% |
| Jan. 2, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | S | Common Stock | 5768 | $54.51 | 86,783.0000 | 53,751,480 | 6.23% | 0.01% |
| Jan. 2, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | S | Common Stock | 200 | $57.37 | 82,139.0000 | 53,751,480 | 0.24% | 0.00% |
| Jan. 2, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | A | Stock option (right to buy) | 63000 | $0.00 | 63,000.0000 | 53,751,480 | 9999.99% | 0.12% |
| Jan. 2, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | S | Common Stock | 3444 | $55.76 | 83,339.0000 | 53,751,480 | 3.97% | 0.01% |
| Jan. 2, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | S | Common Stock | 1000 | $56.78 | 82,339.0000 | 53,751,480 | 1.20% | 0.00% |
| Jan. 2, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | S | Common Stock | 2922 | $53.76 | 92,551.0000 | 53,751,480 | 3.06% | 0.01% |
| Jan. 2, 2025 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | A | Common Stock | 18000 | $0.00 | 95,473.0000 | 53,751,480 | 23.23% | 0.03% |
| Dec. 19, 2024 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | M | Common Stock | 9880 | $20.24 | 77,472.0000 | 54,628,670 | 14.62% | 0.02% |
| Dec. 19, 2024 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | M | Stock Option (right to buy) | 1 | $0.00 | 89,999.0000 | 54,628,670 | 0.00% | 0.00% |
| Dec. 19, 2024 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | M | Stock Option (right to buy) | 9880 | $0.00 | 96,870.0000 | 54,628,670 | 9.26% | 0.02% |
| Dec. 19, 2024 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | M | Common Stock | 1 | $14.02 | 77,473.0000 | 54,628,670 | 0.00% | 0.00% |
| Sept. 27, 2024 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | M | Stock Option (right to buy) | 50000 | $0.00 | 100,667.0000 | 44,016,283 | 33.19% | 0.11% |
| Sept. 27, 2024 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | S | Common Stock | 50000 | $45.96 | 67,592.0000 | 44,016,283 | 42.52% | 0.11% |
| Sept. 27, 2024 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | M | Common Stock | 50000 | $4.21 | 117,592.0000 | 44,016,283 | 73.97% | 0.11% |
| Jan. 2, 2024 | Janux Therapeutics, Inc. | $JANX | Meyer Andrew Hollman | Chief Business Officer | A | Stock Option (right to buy) | 105000 | $0.00 | 105,000.0000 | 44,016,283 | 9999.99% | 0.24% |